Abbonarsi

Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum ?-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiority study - 26/09/19

Doi : 10.1016/S1473-3099(19)30262-2 
Marjolein F Q Kluytmans-van den Bergh, PhD a, b, d, , Patricia C J Bruijning-Verhagen, PhD d, Christina M J E Vandenbroucke-Grauls, ProfPhD f, Els I G B de Brauwer, PhD g, Anton G M Buiting, PhD h, Bram M Diederen, PhD i, j, Erika P M van Elzakker, MD k, Alex W Friedrich, ProfPhD l, Joost Hopman, MD m, Nashwan al Naiemi, PhD n, John W A Rossen, ProfPhD l, Gijs J H M Ruijs, PhD o, Paul H M Savelkoul, ProfPhD f, p, Carlo Verhulst, BASc c, Margreet C Vos, ProfPhD q, Andreas Voss, ProfPhD m, r, Marc J M Bonten, ProfPhD d, e, Jan A J W Kluytmans, ProfPhD a, c, d
on behalf of the

SoM Study Group

  Members listed in the Supplementary Material
Marc Bonten, Martin Bootsma, Els de Brauwer, Patricia Bruijning-Verhagen, Anton Buiting, Bram Diederen, Erika van Elzakker, Alexander Friedrich, Joost Hopman, Greetje Kampinga, Peter van Keulen, Jan Kluytmans, Marjolein Kluytmans-van den Bergh, Nashwan al Naiemi, Guy Oudhuis, Erwin Raangs, Sigrid Rosema, John Rossen, Gijs Ruijs, Paul Savelkoul, Annet Troelstra, Christina Vandenbroucke-Grauls, Kees Verduin, Carlo Verhulst, Margreet Vos, Andreas Voss, Rob Willems, Ina Willemsen

a Department of Infection Control, Amphia Hospital, Breda, Netherlands 
b Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, Netherlands 
c Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands 
d Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands 
e Department of Medical Microbiology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands 
f Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands 
g Department of Medical Microbiology, Atrium Medical Center, Heerlen, Netherlands 
h Laboratory for Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands 
i Regional Laboratory of Public Health, Haarlem, Netherlands 
j Microvida Laboratory for Microbiology, Bravis Hospital, Roosendaal, Netherlands 
k Department of Microbiology, Haga Hospital, The Hague, Netherlands 
l Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands 
m Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands 
n Department of Medical Microbiology and Infection Control, Ziekenhuisgroep Twente, Almelo/Hengelo, Netherlands 
o Laboratory for Microbiology and Infectious Diseases, Isala Clinics, Zwolle, Netherlands 
p Department of Medical Microbiology, Maastricht University Medical Center+, Maastricht, Netherlands 
q Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands 
r Department of Medical Microbiology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands 

* Correspondence to: Dr Marjolein F Q Kluytmans-van den Bergh, Department of Infection Control, Amphia Hospital, 4800 RK Breda, Netherlands Department of Infection Control Amphia Hospital Breda RK 4800 Netherlands

Summary

Background

Use of single-bed rooms for control of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is under debate; the added value when applying contact precautions has not been shown. We aimed to assess whether an isolation strategy of contact precautions in a multiple-bed room was non-inferior to a strategy of contact precautions in a single-bed room for preventing transmission of ESBL-producing Enterobacteriaceae.

Methods

We did a cluster-randomised, crossover, non-inferiority study on medical and surgical wards of 16 Dutch hospitals. During two consecutive study periods, either contact precautions in a single-bed room or contact precautions in a multiple-bed room were applied as the preferred isolation strategy for patients with ESBL-producing Enterobacteriaceae cultured from a routine clinical sample (index patients). Eligible index patients were aged 18 years or older, had no strict indication for barrier precautions in a single-bed room, had a culture result reported within 7 days of culture and before discharge, and had no wardmate known to be colonised or infected with an ESBL-producing Enterobacteriaceae isolate of the same bacterial species with a similar antibiogram. Hospitals were randomly assigned in a 1:1 ratio by computer to one of two sequences of isolation strategies, stratified by university or non-university hospital. Allocation was masked for laboratory technicians who assessed the outcomes but not for patients, treating doctors, and infection-control practitioners enrolling index patients. The primary outcome was transmission of ESBL-producing Enterobacteriaceae to wardmates, which was defined as rectal carriage of an ESBL-producing Enterobacteriaceae isolate that was clonally related to the index patient’s isolate in at least one wardmate. The primary analysis was done in the per-protocol population, which included patients who were adherent to the assigned room type. A 10% non-inferiority margin for the risk difference was used to assess non-inferiority. This study is registered with Nederlands Trialregister, NTR2799.

Findings

16 hospitals were randomised, eight to each sequence of isolation strategies. All hospitals randomised to the sequence single-bed room then multiple-bed room and five of eight hospitals randomised to the sequence multiple-bed room then single-bed room completed both study periods and were analysed. From April 24, 2011, to Feb 27, 2014, 1652 index patients and 12 875 wardmates were assessed for eligibility. Of those, 693 index patients and 9527 wardmates were enrolled and 463 index patients and 7093 wardmates were included in the per-protocol population. Transmission of ESBL-producing Enterobacteriaceae to at least one wardmate was identified for 11 (4%) of 275 index patients during the single-bed room strategy period and for 14 (7%) of 188 index patients during the multiple-bed room strategy period (crude risk difference 3·4%, 90% CI −0·3 to 7·1).

Interpretation

For patients with ESBL-producing Enterobacteriaceae cultured from a routine clinical sample, an isolation strategy of contact precautions in a multiple-bed room was non-inferior to a strategy of contact precautions in a single-bed room for preventing transmission of ESBL-producing Enterobacteriaceae. Non-inferiority of the multiple-bed room strategy might change the current single-bed room preference for isolation of patients with ESBL-producing Enterobacteriaceae and, thus, broaden infection-control options for ESBL-producing Enterobacteriaceae in daily clinical practice.

Funding

Netherlands Organisation for Health Research and Development.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2019  Elsevier Ltd. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 19 - N° 10

P. 1069-1079 - ottobre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Do the right thing
  • Marco De Ambrogi
| Articolo seguente Articolo seguente
  • Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial
  • William O’Riordan, Carrie Cardenas, Elliot Shin, Alissa Sirbu, Lynne Garrity-Ryan, Anita F Das, Paul B Eckburg, Amy Manley, Judith N Steenbergen, Evan Tzanis, Paul C McGovern, Evan Loh, OASIS-2 Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.